The healthcare team at BIS Research, recently, concluded an extensive webinar on ‘Liquid Biopsy: An Emerging Frontier in Early Multicancer Detection’. The webinar was hosted by principal consultant, Nitish Kumar, and senior research analyst, Riya Gupta. The guest on this webinar was Mr. Azeet Narayan, principal scientist at Sema4.

The session was full of industry insights as well as deep marketing intelligence around liquid biopsy technique and its impact on multicancer detection process. Some very critical questions were raised during the session by the attendees, which were duly answered by the panel of speakers.

Here’s an excerpt from the QnA that took place during the webinar:

a)    How do you see the market for end-to-end solutions vs. modular approach such as separate providers for kits and separate providers for analysis software?

According to BIS Research analysis, the liquid biopsy market can be divided according to different offerings into testing services, kits, platform and other consumables. Out of these testing services are expected to dominate the market with a 40-50% market share, followed by platform with a 20-30% market share in 2021. Kits had a market share between 5-15% and Other consumables 15-25% in 2021.

b)    Why do you think extracellular vesicles (EVs) will dominate the liquid biopsy market in the coming future, is it in terms of clinical aspects or plain research aspects?

Most of the EV based products in market currently are for research use only. These products still have been approved for clinical purposes. So, the EV based liquid biopsy market was estimated using those product revenues.

c)    As you said Azeet, there are many sequencer and PCR errors while sequencing, which makes it hard to distinguish true mutants from these errors. How do you make sure that is reduced?

We have come up with a method known as clonal overlapping paired-end sequencing, through which we are sequencing both strands of the DNA individually and then match the mutation overlaps. This way only the true mutations are left and all the instrument mutations can be removed.

d)    How do you expect the liquid biopsy techniques to enter the global market. Which regions are adopting the techniques most quickly?

As per BIS research analysis, North America is expected to dominate the global liquid biopsy market during the forecast period 2022-2032. North America has a high adoption rate of liquid biopsy backed by several healthcare companies working in the region. The U.S. has the highest implementation of PCR, NGS, and other technologies in the globe. On the other hand, Asia-Pacific is expected to witness the highest compound annual growth rate (CAGR) of 15-25% during the forecast period 2022-2032. The growth in the Asia-Pacific market is expected to be further enhanced by other factors such as an increase in healthcare awareness, a steady economy leading to a higher focus on genomic research, and the widespread adoption of genome sequencing as the standard of care.

Interested to learn more about this topic? Watch the complete video below: